Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2535-2545

  Clemens, Daniel L ^a   Lee, Bai Yu ^a   Xue, Min ^b   Thomas, Courtney R ^b   Meng, Huan ^a   Ferris, Daniel ^b   Nel, Andre E ^a   Zink, Jeffrey I ^a,b   Horwitz, Marcus A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; ISONIAZID; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; POLYETHYLENEIMINE; RIFAMPICIN; SILICON DIOXIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACIDIFICATION; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOSOME; HUMAN; HUMAN CELL; INTERNALIZATION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; COLONY COUNT, MICROBIAL; CYCLODEXTRINS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; ISONIAZID; MACROPHAGES; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, TRANSMISSION; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; PHAGOCYTOSIS; POLYETHYLENEIMINE; POROSITY; RIFAMPIN; SILICON DIOXIDE;

EID: 84860147608     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06049-11     Document Type: Article

References (50)

1. Acocella G, et al. 1972. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 13:47-53.
2. Ain Q, Sharma S, Khuller GK, Garg SK. 2003. Alginate based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J. Antimicrob. Chemother. 51:931-938. (Pubitemid 36503426)
3. Anisimova YV, Gelperina SI, Peloquin CA, Heifets LB. 2000. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2:165-171. (Pubitemid 33230011)
4. Barbé C, et al. 2004. Silica particles: a novel drug-delivery system. Adv. Mater. 16:1959-1966.
5. Boussif O, et al. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92:7297-7301.
6. Cao Z, Sun Y. 2009. Chitosan-based rechargeable long-term antimicrobial and biofilm-controlling systems. J. Biomed. Mater. Res. A 89:960-967.
7. Cauda V, Schlossbauer A, Bein T. 2010. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microporous Mesoporous Mater. 132:60-71.
8. Chen H, et al. 2010. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PγMPS copolymer coating. Biomaterials 31:5397-5407.
9. Clemens DL, Lee BY, Horwitz MA. 2004. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72:3204-3217. (Pubitemid 38697741)
10. Coti KK, et al. 2009. Mechanised nanoparticles for drug delivery. Nanoscale 1:16-39.
11. Dailey LA, et al. 2006. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 215:100-108. (Pubitemid 44118400)
12. Devarajan PV, et al. 2010. Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J. Pharm. Sci. 99:2576-2581.
13. Du L, Liao S, Khatib HA, Stoddart JF, Zink JI. 2009. Controlled-access hollow mechanized silica nanocontainers. J. Am. Chem. Soc. 131:15136-15142.
14. Duan H, Nie S. 2007. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J. Am. Chem. Soc. 129:3333-3338.
15. Ferris DP, et al. 2009. Light-operated mechanized nanoparticles. J. Am. Chem. Soc. 131:1686-1688.
16. Foradada M, Pujol MD, Bermudez J, Estelrich J. 2000. Chemical deg- radation of liposomes by serum components detected by NMR. Chem. Phys. Lipids 104:133-148. (Pubitemid 30009875)
17. Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172:1487-1490. (Pubitemid 43076534)
18. Giri S, Trewyn BG, Lin VS. 2007. Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine (Lond.) 2:99-111. (Pubitemid 46845781)
19. Gratton SE, et al. 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U. S. A. 105:11613-11618.
20. Griffiths G, Nystrom B, Sable SB, Khuller GK. 2010. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat. Rev. Microbiol. 8:827-834.
21. He Q, Zhang Z, Gao F, Li Y, Shi J. 2011. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 7:271-280.
22. Huang X, Teng X, Chen D, Tang F, He J. 2010. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 31:438-448.
23. Kisich KO, et al. 2007. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm. 345:154-162. (Pubitemid 350087550)
24. Lam KH, Schakenraad JM, Esselbrugge H, Feijen J, Nieuwenhuis P. 1993. The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. J. Biomed. Mater. Res. 27:1569-1577. (Pubitemid 23341485)
25. Lee JE, et al. 2010. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J. Am. Chem. Soc. 132:552-557.
26. Lin VS. 2009. Nanomedicine: veni, vidi, vici and then . . . vanished. Nat. Mater. 8:252-253.
27. Liong M, et al. 2009. Mesostructured multifunctional nanoparticles for imaging and drug delivery. J. Mater. Chem. 19:6251-6257.
28. Liong M, et al. 2008. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-896.
29. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. 2010. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6:1794-1805.
30. Lu J, Liong M, Zink JI, Tamanoi F. 2007. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341-1346. (Pubitemid 47245524)
31. Malabarba A, Ferrari P, Depaoli A, Gallo GG, Cavalleri B. 1986. Synthesis and conformation of some acetyl derivatives of rifampicin. Farmaco Sci. 41:131-150. (Pubitemid 16152011)
32. Marques AP, Reis RL, Hunt JA. 2004. Cytokine secretion from mononuclear cells cultured in vitro with starch-based polymers and poly-Llactide. J. Biomed. Mater. Res. A 71:419-429. (Pubitemid 39488514)
33. Meng H, et al. 2010. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4:4539-4550.
34. Meng H, et al. 2011. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5:4131-4144.
35. Meng H, et al. 2010. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 132:12690-12697.
36. Miceli NJ, Olson WA, Weber WW. 1975. An improved micro spectrofluorometric assay for determining isoniazid in serum. Biochem. Med. 12:348-355.
37. Muttil P, et al. 2007. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32:140-150. (Pubitemid 47285721)
38. National Institute of Public Health P. 2010. WHO global tuberculosis control report 2010. Summary. Cent. Eur. J. Public Health 18:237.
39. Pandey R, Khuller GK. 2005. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb.) 85:227-234. (Pubitemid 40805619)
40. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. 2010. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 385:143-149.
41. Semete B, et al. 2010. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6:662-671.
42. Semete B, et al. 2010. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol. Appl. Pharmacol. 249:158-165.
43. Sharma A, Sharma S, Khuller GK. 2004. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54:761-766. (Pubitemid 39386728)
44. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. 2010. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 62:547-559.
45. Souris JS, et al. 2010. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 31:5564-5574.
46. van Hest R, et al. 2004. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin. Infect. Dis. 39:488-496.
47. Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. 2010. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6:1952-1967.
48. Xia T, et al. 2009. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3:3273-3286.
49. Xue M, et al. 2011. pH-operated mechanized porous silicon nanoparticles. J. Am. Chem. Soc. 133:8798-8801.
50. Zhao Y, Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. 2010. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin. Drug Deliv. 7:1013-1029.